Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment

References

• Mongiu AK, McVary KT. Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity. Curr Prostate Rep 2009;7:63–9.
   Google Scholar
• Abrams P, Chapple C, Khoury S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2008;181:1779–87.
   Web of Science ®Google Scholar
• Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America Project: benign prostatic hyperplasia. J Urol 2005;173:1256–61.
   PubMed Web of Science ®Google Scholar
• Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among men with limited life expectancies. JAMA 2006;296:2336–42.
   PubMed Web of Science ®Google Scholar
• Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976;48:255–63.
   PubMedGoogle Scholar
• Tyagi P, Tyagi V, Chancellor M. Mirabegron: a safety review. Expert Opin Drug Saf 2011;10:287–94.
   PubMed Web of Science ®Google Scholar
• Kaplan SA. Side effects of α-blocker use: retrograde ejaculation. Rev Urol 2009;11:S14–18.
   PubMedGoogle Scholar
• Nagai A, Hara R, Yokoyama T, et al. Ejaculatory dysfunction caused by the new a-1 blocker silodosin: a preliminary study to analyze human ejaculation using color doppler ultrasonography. Int J Urol 2008;15:915–18.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006;176:1529–33.
   PubMed Web of Science ®Google Scholar
• Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019–24.
   PubMed Web of Science ®Google Scholar
• Handzel DM, Briesen S, Rausch S, Kälble T. Cataract surgery in patients taking alpha-1 antagonists. Dtsch Arztebl Int 2012;109:379–84.
   PubMed Web of Science ®Google Scholar
• Lepor H. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate 1990;17:75–84.
   Google Scholar
• Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004;6:S31–9.
   PubMedGoogle Scholar
• Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best-case management. Can J Urol 2011;18:14–19.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98.
   PubMed Web of Science ®Google Scholar
• Carlin BI, Seftel AD, Resnik MI, Findlay J. Finasteride induced gynecomastia. J Urol 1997;158:547.
   PubMed Web of Science ®Google Scholar
• Thompson I, Goodman P, Tangen C, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.
   PubMed Web of Science ®Google Scholar
• Schitz-Drager BJ, Fischer C, Bismarck E, et al. The prostate cancer prevention trial: relevance for clinical practice. Urologe A 2007;46:1364–8.
   PubMedGoogle Scholar
• Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917–25.
   PubMed Web of Science ®Google Scholar
• Wilt T, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280:1604–9.
   PubMed Web of Science ®Google Scholar
• Marks L, Partin A, Epstein J, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451–6.
   PubMed Web of Science ®Google Scholar
• Wagreli L, Schelin S, Nordling J, et al. Feedback microwave thermotherapy versus TURP for clinical BPH-a randomized controlled multicenter study. Urology 2002;60:292–9.
   PubMed Web of Science ®Google Scholar
• Bruskewitz R, Issa MM, Roehborn CH, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998;159:1588–94.
   PubMed Web of Science ®Google Scholar
• Malek R, Kuntzman R, Barrett D. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 2005;174:1344–8.
   PubMed Web of Science ®Google Scholar
• Kupeli S, Baltaci S, Soygur T, et al. A prospective randomized study of transurethral resection of the prostate and transurethral vaporization of the prostate as a therapeutic alternative in the management of men with BPH. Eur Urol 1998;34:15–18.
   PubMed Web of Science ®Google Scholar
• Smith D, Khoubehi B, Patel A. Bipolar electrosurgery for benign prostatic hyperplasia: transurethral electrovaporization and resection of the prostate. Curr Opin Urol 2005;15:95–100.
   PubMed Web of Science ®Google Scholar